Start with osteoarthritis, then reuse UniProt P46663 as the stable protein anchor across project notes and exports.
CHEMBL4308 Target Snapshot
B1 bradykinin receptor · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14B1 bradykinin receptor shows clinical signal disease relevance led by osteoarthritis. 2 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P46663. Start with osteoarthritis, then reuse UniProt P46663 as the stable protein anchor across project notes and exports.
B1 bradykinin receptor shows clinical signal disease relevance led by osteoarthritis. 2 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with osteoarthritis because it currently carries clinical signal support. Linked drugs include BI113823, MK0686. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyB1 bradykinin receptor
Review this target as B1 bradykinin receptor, mapped to UniProt P46663. Sequence length is 353 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats B1 bradykinin receptor as ChEMBL target CHEMBL4308, mapped to UniProt P46663. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether B1 bradykinin receptor is the right protein anchor across sources, using UniProt P46663 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why osteoarthritis is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | B1 bradykinin receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P46663 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | B1 bradykinin receptor |
| UniProt Accession | P46663 |
| Component Type | Protein |
| Sequence Length | 353 aa |
B1 bradykinin receptor
How to read this target
Review this target as B1 bradykinin receptor, mapped to UniProt P46663. Sequence length is 353 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
B1 bradykinin receptor shows clinical signal disease relevance led by osteoarthritis. 2 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with osteoarthritis because it currently carries clinical signal support. Linked drugs include BI113823, MK0686. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL160547 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL359553 | 10.82 | Kd | 0.015 | Preclinical |
| CHEMBL185693 | 10.7 | Ki | 0.02 | Preclinical |
| CHEMBL359553 | 10.7 | Ki | 0.02 | Preclinical |
| CHEMBL3085458 | 10.64 | Ki | 0.023 | Preclinical |
| CHEMBL189123 | 10.52 | Ki | 0.03 | Preclinical |
| CHEMBL3142391 | 10.46 | Ki | 0.035 | Preclinical |
| CHEMBL359553 | 10.4 | IC50 | 0.04 | Preclinical |
| CHEMBL1939755 | 10.35 | Ki | 0.045 | Preclinical |
| CHEMBL425588 | 10.35 | Ki | 0.045 | Preclinical |
pChEMBL Value Distribution
Assay Landscape
Binding — 112 assays, 603 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 74 | 287 | 7.8 |
| cell-based format | 31 | 244 | 8.0 |
| assay format | 5 | 71 | 8.8 |
| cell membrane format | 2 | 1 | 10.8 |
Functional — 51 assays, 486 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 22 | 305 | 7.9 |
| assay format | 12 | 116 | 7.8 |
| tissue-based format | 9 | 5 | 6.1 |
| organism-based format | 7 | 0 | — |
| single protein format | 1 | 60 | 8.5 |
ADME — 3 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 3 | 0 | — |